Less
than
1%
of
cancer
therapies
reach
intratumoral
Targets.
We're
Fixing
that.
We are developing next-gen biovectors for precise, targeted therapeutic delivery, with applications ranging from cancer treatment to gene therapy.
We are developing next-gen biovectors for precise, targeted therapeutic delivery, with applications ranging from cancer treatment to gene therapy.
We are developing next-gen biovectors for precise, targeted therapeutic delivery, with applications ranging from cancer treatment to gene therapy.
Molecular Therapy
Laboratory Practice
Extracellular Vesicles
Medical Oncology
Cancer Research
VISION
Enabling breakthrough medicines achieve the outcomes they were designed for.
We unlock the full therapeutic potential of innovative drug candidates through our next-generation nanomedicine delivery platform. We transform today's innovations into tomorrow's cures by de-risking clinical programs and amplifying therapeutic impact for patients. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.
VISION
Enabling breakthrough medicines achieve the outcomes they were designed for.
We unlock the full therapeutic potential of innovative drug candidates through our next-generation nanomedicine delivery platform. We transform today's innovations into tomorrow's cures by de-risking clinical programs and amplifying therapeutic impact for patients. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.
VISION
Enabling breakthrough medicines achieve the outcomes they were designed for.
We unlock the full therapeutic potential of innovative drug candidates through our next-generation nanomedicine delivery platform. We transform today's innovations into tomorrow's cures by de-risking clinical programs and amplifying therapeutic impact for patients. We want to establish our biovectors as the universal standard for targeted therapeutic delivery.
The science is ready. The moment is now.
The science is ready. The moment is now.
THE SYNAMETA SOLUTION
What If Every Molecule Reached Its Destination?
THE SYNAMETA SOLUTION
What If Every Molecule Reached Its Destination?
THE SYNAMETA SOLUTION
What If Every Molecule Reached Its Destination?
Virus-Free Architecture
No viral components. Reduced Immunogenicity. Safer and easier to perform.
Virus-Free Architecture
No viral components. Reduced Immunogenicity. Safer and easier to perform.
Virus-Free Architecture
No viral components. Reduced Immunogenicity. Safer and easier to perform.
Active Fusogen Integration
Endogenous human fusogens trigger direct membrane fusion.
Active Fusogen Integration
Endogenous human fusogens trigger direct membrane fusion.
Active Fusogen Integration
Endogenous human fusogens trigger direct membrane fusion.
Universal Payload Platform
One vector, infinite applications. Multi-indication from day one.
Universal Payload Platform
One vector, infinite applications. Multi-indication from day one.
Universal Payload Platform
One vector, infinite applications. Multi-indication from day one.
Universal Cargo Flexibility
Our technology is dedicated to load peptide based drug, proteins, toxins, genome editors, existing drugs.
Universal Cargo Flexibility
Our technology is dedicated to load peptide based drug, proteins, toxins, genome editors, existing drugs.
Universal Cargo Flexibility
Our technology is dedicated to load peptide based drug, proteins, toxins, genome editors, existing drugs.
Cell-Specific Tethering
Proprietary targeting system directs delivery exclusively to malignant cells, sparing healthy tissue.
Cell-Specific Tethering
Proprietary targeting system directs delivery exclusively to malignant cells, sparing healthy tissue.
Cell-Specific Tethering
Proprietary targeting system directs delivery exclusively to malignant cells, sparing healthy tissue.
Preclinically Validated
All components validated ex vivo. In vivo murine models underway. Data package ready.
Preclinically Validated
All components validated ex vivo. In vivo murine models underway. Data package ready.
Preclinically Validated
All components validated ex vivo. In vivo murine models underway. Data package ready.
Molecular Therapy
Laboratory Practice
Extracellular Vesicles
Medical Oncology
Cancer Research
COMPETITIVE ADVANTAGE
Legacy Systems Weren't Built for This
COMPETITIVE ADVANTAGE
Legacy Systems Weren't Built for This
COMPETITIVE ADVANTAGE
Legacy Systems Weren't Built for This
Viral Vectors
Viral Vectors
Viral Vectors
Immune rejection blocks re-dosing
Immune rejection blocks re-dosing
Immune rejection blocks re-dosing
Fixed cargo limitations
Fixed cargo limitations
Fixed cargo limitations
Passive diffusion hoping
Passive diffusion hoping
Passive diffusion hoping
Immunogenicity regulatory barriers
Immunogenicity regulatory barriers
Immunogenicity regulatory barriers
Single-indication constraint
Single-indication constraint
Single-indication constraint
Safe repeat treatments
Safe repeat treatments
Safe repeat treatments
Universal payload compatibility
Universal payload compatibility
Universal payload compatibility
Active fusogen-mediated infiltration
Active fusogen-mediated infiltration
Active fusogen-mediated infiltration
Human-derived regulatory advantage
Human-derived regulatory advantage
Human-derived regulatory advantage
Pan-indication platform scalability
Pan-indication platform scalability
Pan-indication platform scalability
We don't bypass biology. We leverage it natively.
Team
Built by Scientists Who Solved the Hard Problem First
Twenty years in elite labs. Now building the company that makes it matter.
Team
Built by Scientists Who Solved the Hard Problem First
Twenty years in elite labs. Now building the company that makes it matter.
Team
Built by Scientists Who Solved the Hard Problem First
Twenty years in elite labs. Now building the company that makes it matter.
CEO
Dr. Sandra Oucher
Member Board of Directors at the Paris-Saclay Foundation Ex-Sanofi Global Clinical Development, French leading BioPharma Company Ex-CEO Right Hand at EVerZom, a leading exosomes' manufacturing company Ex-researcher in immuno-oncology at Gustave Roussy, France
CEO
Dr. Sandra Oucher
Member Board of Directors at the Paris-Saclay Foundation Ex-Sanofi Global Clinical Development, French leading BioPharma Company Ex-CEO Right Hand at EVerZom, a leading exosomes' manufacturing company Ex-researcher in immuno-oncology at Gustave Roussy, France
CEO
Dr. Sandra Oucher
Member Board of Directors at the Paris-Saclay Foundation Ex-Sanofi Global Clinical Development, French leading BioPharma Company Ex-CEO Right Hand at EVerZom, a leading exosomes' manufacturing company Ex-researcher in immuno-oncology at Gustave Roussy, France
CSO
Dr. Grégory Lavieu
Director of the Lavieu Lab, INSERM Permanent Investigator, Chaire d'Excellence Université de Paris Expert in cell biology/biochemistry specializing in membrane traffic Ex-Berkeley Lights, Inc. Ex-Yale University, USA
CSO
Dr. Grégory Lavieu
Director of the Lavieu Lab, INSERM Permanent Investigator, Chaire d'Excellence Université de Paris Expert in cell biology/biochemistry specializing in membrane traffic Ex-Berkeley Lights, Inc. Ex-Yale University, USA
CSO
Dr. Grégory Lavieu
Director of the Lavieu Lab, INSERM Permanent Investigator, Chaire d'Excellence Université de Paris Expert in cell biology/biochemistry specializing in membrane traffic Ex-Berkeley Lights, Inc. Ex-Yale University, USA
COO & GC
Lorenzo Fanti
Currently VP Legal and Chief Compliance Officer at (another) highly innovative medtech company, ONWARD Medical, Lorenzo is a dual- qualified US and English attorney Ex-Novartis Global Legal Head Ex-Sandoz Trademark paralegal Ex-Allen & Overy LLP, UK
COO & GC
Lorenzo Fanti
Currently VP Legal and Chief Compliance Officer at (another) highly innovative medtech company, ONWARD Medical, Lorenzo is a dual- qualified US and English attorney Ex-Novartis Global Legal Head Ex-Sandoz Trademark paralegal Ex-Allen & Overy LLP, UK
COO & GC
Lorenzo Fanti
Currently VP Legal and Chief Compliance Officer at (another) highly innovative medtech company, ONWARD Medical, Lorenzo is a dual- qualified US and English attorney Ex-Novartis Global Legal Head Ex-Sandoz Trademark paralegal Ex-Allen & Overy LLP, UK
Pharma. Investors. Innovators.
We're raising in pre-seed capital to complete preclinical validation and onboard strategic pharma partners into our flexible 4-6 month research programs. If you know delivery not discovery determines therapeutic success, and exosomes represent evolution's answer, let's build this together.
Pharma. Investors. Innovators.
We're raising in pre-seed capital to complete preclinical validation and onboard strategic pharma partners into our flexible 4-6 month research programs. If you know delivery not discovery determines therapeutic success, and exosomes represent evolution's answer, let's build this together.
Pharma. Investors. Innovators.
We're raising in pre-seed capital to complete preclinical validation and onboard strategic pharma partners into our flexible 4-6 month research programs. If you know delivery not discovery determines therapeutic success, and exosomes represent evolution's answer, let's build this together.